Novavax (MEX:NVAX) Other Gross PPE : MXN4,765 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Novavax Other Gross PPE?

Novavax's Other Gross PPE for the quarter that ended in Dec. 2024 was MXN4,765 Mil.

Novavax's quarterly Other Gross PPE increased from Jun. 2024 (MXN8,392 Mil) to Sep. 2024 (MXN8,890 Mil) but then declined from Sep. 2024 (MXN8,890 Mil) to Dec. 2024 (MXN4,765 Mil).

Novavax's annual Other Gross PPE increased from Dec. 2022 (MXN2,440 Mil) to Dec. 2023 (MXN3,964 Mil) and increased from Dec. 2023 (MXN3,964 Mil) to Dec. 2024 (MXN4,765 Mil).

Novavax Other Gross PPE Historical Data

The historical data trend for Novavax's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Other Gross PPE Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

Get a 7-Day Free Trial

192.63

1,034.01

2,439.65

3,963.96

4,764.92

Novavax Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															3,963.96	7,837.88	8,391.82	8,889.97	4,764.92

Novavax Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.